| 產(chǎn)品編號 | bs-0080R-Gold |
| 英文名稱(chēng) | Rabbit Anti-CD20/Gold Conjugated antibody |
| 中文名稱(chēng) | 膠體金標記的CD20抗體 |
| 別 名 | CD20_HUMAN; B-lymphocyte antigen CD20; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1; MS4A1; MS4A2; B1; CVID5; LEU-16; S7. |
| 規格價(jià)格 | 100ul/2980元 購買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 干細胞 細胞表面分子 細胞類(lèi)型標志物 淋巴細胞 b-淋巴細胞 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應 | Human, Rat, (predicted: Mouse, Dog, Cow, Rabbit, ) |
| 產(chǎn)品應用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 33kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD20 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: CD20 is a non glycosylated protein with a molecular weight of 35 or 37 kDa depending on the degree of phosphorylation. Although not a member of the tetraspanin superfamily of cell surface receptors, it crosses the cell membrane four times. The CD20 antigen is present on human pre B lymphocytes and on B lymphocytes at all stages of maturation, except on plasma cells. Low level expression of the CD20 antigen has been detected on normal T lymphocytes. The CD20 molecule is involved in regulation of B cell differentiation, presumably via its reported function as a Ca++ channel subunit. Function: This protein may be involved in the regulation of B-cell activation and proliferation Subcellular Location: Membrane; Multi-pass membrane protein. Tissue Specificity: Expressed on B-cells. Post-translational modifications: Phosphorylated. Might be functionally regulated by protein kinase(s). DISEASE: Defects in MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5) [MIM:613495]; also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. Similarity: Belongs to the MS4A family. Database links: Entrez Gene: 931 Human Omim: 112210 Human SwissProt: P11836 Human Unigene: 712553 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. [PHARMACEUTICAL] Monoclonal antibodies (mAb) against CD20 are used to treat B-cell non-Hodgkin lymphoma (NHL). These antibodies include Rituximab (Mabthera), Britumomab (Zevalin) and Tositumomab (Bexxar). CD20 engaged by mAb can generate transmembrane signals capable of directly controlling cell growth and triggering cell death in certain tumors. Alternatively, mAb can mediate complement-dependent cytotoxicity. B淋巴細胞標志物 CD20是B細胞特異性抗原，其表達呈細胞類(lèi)型一種質(zhì)膜蛋白質(zhì)，參與信號傳導作用，此抗體識別大多數B細胞上的一種抗原。多用于標記B淋巴細胞及B細胞淋巴瘤。 CD20一般不與T細胞交叉反應，對B細胞淋巴瘤和急慢性淋巴細胞白血病等有較好的細胞特異性，因此在惡性淋巴瘤，尤其是T或B細胞淋巴瘤的分類(lèi)上，CD20是最常用的B細胞標志。 |
